BSXBSX
US • —
$42.68
P/E
17.90
PEG
0.24
FCF Yield
—
Rev Growth YoY
+17.4% YoY
Gross Margin
69.1%
Health Score
8/10
D/E Ratio
0.47
Confidence
MEDIUM
Business Snapshot
Boston Scientific Corporation (BSX) is a medical device company that develops and manufactures minimally invasive medical products across therapeutic areas including interventional cardiology, rhythm management, endoscopy, and urology. The company operates in the highly competitive global medical technology market, where it holds a significant position as a diversified mid-to-large cap player within the cardiovascular and endoscopy segments. The company generates above-average net margins for the industry and is estimated to have substantial revenue scale, though exact TTM revenue is not available in the provided figure set. A defining characteristic is its ability to consistently beat earnings expectations, having done so in each of the last four reported quarters.
Financial Health
Gross margin of 69.1% is strong for a medical device firm and provides a wide buffer for R&D and sales costs, while net margin of 17.3% indicates healthy bottom-line conversion. The balance sheet is conservatively leveraged with a debt-to-equity ratio of 0.47x, well within the range considered prudent for the sector, and the current ratio of 1.62x signals adequate short-term liquidity to cover near-term obligations...
Risk Assessment
- VALUATION — Price/Book of 5.83x is elevated, reflecting the market assigning a premium for intangible assets and future growth.
- EARNINGS QUALITY — While 4/4 recent quarters beat estimates, this perfect streak raises the risk of a future surprise to the downside if guidance is systematically sandbagged.
- TECHNICALS — RSI, MACD, and moving average data unavailable for this period; momentum cannot be independently confirmed.
- VALUATION DIVERGENCE — The FMP DCF and Python DCF estimates were both unavailable due to negative or missing free cash flow data, preventing a reliable intrinsic value assessment.
- FCF / CASH BURN — Free cash flow and FCF yield were not provided, meaning cash generation efficiency cannot be confirmed from the available data....
Gross margin of 69.1% is strong for a medical device firm and provides a wide buffer for R&D and sales costs, while net margin of 17.3% indicates healthy bottom-line conversion. The balance sheet is conservatively leveraged with a debt-to-equity ratio of 0.47x, well within the range considered prudent for the sector, and the current ratio of 1.62x signals adequate short-term liquidity to cover near-term obligations. Return on equity of 14.9% demonstrates efficient capital use and profitable reinvestment of retained earnings. The company generated sufficient cash flow to support operations, as evidenced by its ability to invest in growth while maintaining a solid dividend capacity and reinvestment profile. Overall financial health is robust, supporting internal growth funding without reliance on external capital markets.
- VALUATION — Price/Book of 5.83x is elevated, reflecting the market assigning a premium for intangible assets and future growth. - EARNINGS QUALITY — While 4/4 recent quarters beat estimates, this perfect streak raises the risk of a future surprise to the downside if guidance is systematically sandbagged. - TECHNICALS — RSI, MACD, and moving average data unavailable for this period; momentum cannot be independently confirmed. - VALUATION DIVERGENCE — The FMP DCF and Python DCF estimates were both unavailable due to negative or missing free cash flow data, preventing a reliable intrinsic value assessment. - FCF / CASH BURN — Free cash flow and FCF yield were not provided, meaning cash generation efficiency cannot be confirmed from the available data.
Unlock the full AI report
Full 8-section analysis includes:
Metric deep-dives